HPV Vaccination: Can It Prevent CIN3 and AIS?
HPV Vaccination: Can It Prevent CIN3 and AIS?
Hello. I am Dr. Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss the recent report that appeared in the Lancet Oncology describing the effects of the HPV-16/18 vaccine for the prevention of persistent infection with this oncogenic virus in young women. I think everyone who is listening to this presentation is aware of the rather dramatic results associated with human papillomavirus (HPV) vaccination in this arena.
One question that has persisted is how effective such vaccination is in preventing the most serious complications associated with infection with HPV 16 and 18, specifically cervix cancer and the precursor lesions, cervical intraepithelial neoplasia grade 3 (CIN3) and adenocarcinoma in situ.
In this report, which appeared in the Lancet Oncology, the results were nothing but spectacular. In a population of more than 11,000 young women who participated in this landmark trial, specifically women who were naive to HPV-16 or -18 infection at the time of vaccination, the vaccination strategy was essentially 100% effective in that there were no cases of CIN3 or adenocarcinoma in situ compared with 20 cases of CIN3 and 6 cases of adenocarcinoma in situ in the control population.
I think these results emphasize the extreme importance of HPV vaccination in all young women. They demonstrate that this vaccine, in future years, will clearly be shown to have a major impact on public health in general and on the health of the individual women who have undergone vaccination. Additionally, this study emphasizes that all clinicians should do their best to make sure that the population understands the benefits of HPV vaccination.
I thank you for your attention and I encourage you to read this paper that appeared in the Lancet Oncology. Thank you.
Hello. I am Dr. Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss the recent report that appeared in the Lancet Oncology describing the effects of the HPV-16/18 vaccine for the prevention of persistent infection with this oncogenic virus in young women. I think everyone who is listening to this presentation is aware of the rather dramatic results associated with human papillomavirus (HPV) vaccination in this arena.
One question that has persisted is how effective such vaccination is in preventing the most serious complications associated with infection with HPV 16 and 18, specifically cervix cancer and the precursor lesions, cervical intraepithelial neoplasia grade 3 (CIN3) and adenocarcinoma in situ.
In this report, which appeared in the Lancet Oncology, the results were nothing but spectacular. In a population of more than 11,000 young women who participated in this landmark trial, specifically women who were naive to HPV-16 or -18 infection at the time of vaccination, the vaccination strategy was essentially 100% effective in that there were no cases of CIN3 or adenocarcinoma in situ compared with 20 cases of CIN3 and 6 cases of adenocarcinoma in situ in the control population.
I think these results emphasize the extreme importance of HPV vaccination in all young women. They demonstrate that this vaccine, in future years, will clearly be shown to have a major impact on public health in general and on the health of the individual women who have undergone vaccination. Additionally, this study emphasizes that all clinicians should do their best to make sure that the population understands the benefits of HPV vaccination.
I thank you for your attention and I encourage you to read this paper that appeared in the Lancet Oncology. Thank you.
Source...